First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung CancerBenjamin Solomon, Fiona Blackhall, Jolanda Paolini et al.|New England Journal of Medicine|2014Cited by 3.2k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trialHoward West, Federico Cappuzzo, Michael McCleod et al.|The Lancet Oncology|2019Cited by 1.7k
Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell CarcinomaTarek Mekhail, Ronald M. Bukowski|Journal of Clinical Oncology|2005Cited by 571
Diagnosis of lung cancer by the analysis of exhaled breath with a colorimetric sensor arrayPeter J. Mazzone, Tarek Mekhail|Thorax|2007Cited by 324
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung CancerCaicun Zhou, Pasi A. Jänne, Huamao Mark Lin et al.|JAMA Oncology|2021Cited by 289